GSK Pharmaceuticals Reports Q2 Results and Key Leadership Appointments
GlaxoSmithKline Pharmaceuticals Ltd · Financial Result · 04 Nov 2026, 12:27 am
GSK Pharmaceuticals Reports Q2 Results and Key Leadership Appointments GlaxoSmithKline Pharmaceuticals reported consolidated revenue of ₹1,183.57 crore for the quarter ended 30th Sep'26, up 20.8% YoY from ₹979.94 crore. Net profit grew 30.4% YoY to ₹335.88 crore, compared to ₹257.49 crore in the prior-year period, supported by ₹72.78 crore in other income (including ₹42.09 crore tax refund interest). Basic EPS stood at ₹19.83. The board approved the appointment of Sandeep Seth as Head - Ethics & Compliance and proposed Walker Chandiok & Co LLP as Statutory Auditors for five years starting FY28.
Original exchange filing (PDF)
More announcements from GlaxoSmithKline Pharmaceuticals Ltd
- As per attachment · 08 Nov 2026
- As per attachment · 05 Nov 2026
- As per attachment · 05 Nov 2026
- Analyst meet Presentation · 04 Nov 2026
- As per attachment · 04 Nov 2026
- As per attachment · 04 Nov 2026
- As per attachment · 04 Nov 2026
- GlaxoSmithKline Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 04 Nov 2026
